US Patent Issued to SHANGHAI MEIZER PHARMACEUTICALS on May 12 for "Compound for targeted degradation of BTK and anti-tumour use thereof" (Chinese Inventors)

ALEXANDRIA, Va., May 12 -- United States Patent no. 12,624,042, issued on May 12, was assigned to SHANGHAI MEIZER PHARMACEUTICALS Co. LTD. (Shanghai).

"Compound for targeted degradation of BTK and anti-tumour use thereof" was invented by Yongzhi Shu (Shanghai) and Fengjun Luo (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided in the present invention are a compound for the targeted degradation of BTK and the anti-tumor use thereof. In particular, in the present invention, a series of compounds are prepared and screened, the inhibitory and degradation activities of said compounds against Bruton's tyrosine kinase (BTK) are verified, and finally a compound with good druggability is found. The com...